NFKB1 and osteoporosis: Previous studies have reported that NEMO-binding-domain peptides with inhibitory effects upstream of the NF-κB signaling cascade are effective in animal models of osteoporosis; however, none of these peptides have been used in clinical settings (24, 60–62).